Polytech Ventures

Polytech Ventures operates from Lausanne with deep ties to the EPFL ecosystem, which positions it close to one of the most consistent sources of technical talent and applied research in continental Europe. The firm is small, early-stage, and explicitly focused on commercializing what comes out of EPFL labs and the broader Swiss research environment, particularly in software and machine learning.

The healthcare thesis covers digital health and AI/ML in healthcare, with a bias toward data-driven software and machine learning applications rather than therapeutics or devices. In practice that means companies whose origin story includes an EPFL lab, a research collaboration, or a Swiss clinical partnership, with the commercial work largely ahead of them. Specific portfolio companies are not enumerated in the source material, so founders should request direct references in diligence.

The firm invests at Pre-Seed and Seed only, with checks of two hundred fifty thousand to one million dollars. That stage discipline is genuine and worth taking at face value: Polytech is an early lead or co-investor on small rounds, not a Series A anchor. The geographic focus is Switzerland with selective activity in surrounding European markets. For founders building near EPFL or with early Swiss clinical partners, the firm’s local depth shortens the path to first reference customers and follow-on syndicate introductions, which is materially useful at Seed.

The team is built around partners with backgrounds in technology investing and operating roles, with strong connectivity into the EPFL and Swiss research network. Specific partner names are not provided in the source material, and founders should clarify partner ownership of healthcare directly.

The right founders for Polytech are technical teams emerging from or anchored in the Swiss research ecosystem, building data-driven healthcare software where local clinical and academic relationships meaningfully accelerate the early commercial path. The wrong founders are companies with no Swiss anchor and no specific need for what the EPFL ecosystem provides, where the firm’s value is harder to capture. Founders should arrive with a clear plan for early clinical reference sites, an honest assessment of regulatory pathway, and a credible follow-on syndicate strategy, since check size makes Polytech a Seed-only partner rather than a continuation investor. The firm is well-suited to founders who want a research-cluster investor that can be hands-on at the earliest stage.